Clinical Progress O.S. Therapies is a clinical stage biotech advancing OST-HER2 with a PhIIb trial expected to complete in 4Q2024 and shows signals of improved Event Free Survival and early Overall Survival, suggesting a timely market readiness and potential near-term expansion opportunities with oncology-focused partners and trial collaborations.

Strategic Partnerships Recent activity includes a senior secured convertible notes financing and advisory/partnership announcements with EVERSANA for US commercialization of OST-HER2 in pediatric lung metastatic osteosarcoma, indicating momentum in channel partnerships and potential collaboration avenues for broader market access and launch support.

Executive Engagement Addition of a seasoned Chief Medical Advisor and active participation in industry events (BioFuture 2025, technology and osteosarcoma conferences) signal a focus on clinical credibility and thought leadership, creating outreach openings for pharmaceutical co-development talks and advisory collaborations.

Technology & IP OST-tADC represents a novel pH-sensitive Drug Conjugate leveraging proprietary Silicon technology to target acidic tumor environments, presenting a unique IP moat and potential licensing or co-development discussions with partners seeking innovative payload delivery platforms.

Funding & Growth With a funding total of around $37M and 11-50 employees, OS Therapies is positioned for targeted preclinical-to-clinical milestones and potential capital-efficient partnerships, making it attractive for strategic investors, CROs, and specialty biotech buyers seeking early-stage oncology assets.